Publication
The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage
| dc.contributor.author | Barbosa, MD | |
| dc.contributor.author | Arthur, AS | |
| dc.contributor.author | Louis, RH | |
| dc.contributor.author | MacDonald, T | |
| dc.contributor.author | Polin, RS | |
| dc.contributor.author | Gazak, C | |
| dc.contributor.author | Kassell, NF | |
| dc.date.accessioned | 2011-01-20T16:00:52Z | |
| dc.date.available | 2011-01-20T16:00:52Z | |
| dc.date.issued | 2001 | |
| dc.description.abstract | OBJECTIVE: Eicosanoids have been implicated in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH). Leukotrienes, 5-hydroxyperoxyeicosatetraenoic acid, and 5-hydroxyeicosatetraenoic acid are part of this group of substances, resulting from the 5-lipoxygenase activity on arachidonic acid metabolism. This study examined the effects of ABT-761, a new 5-lipoxygenase inhibitor, on cerebral vasospasm in an in vivo rabbit model of SAH. METHODS: A total of 48 rabbits were assigned to one of six groups: SAH + placebo (n = 8), SAH + ABT-761 20 mg/kg (n = 8), SAH + ABT-761 30 mg/kg (n = 8), control + placebo (n = 8), control + ABT-761 20 mg/kg (n = 8), and control + ABT-761 30 mg/kg (n = 8). Drug administration was initiated 30 minutes after induction of SAH and repeated 24 hours later. The animals were killed 48 hours after SAH, using the perfusion-fixation method. The cross sectional areas of basilar artery histological sections were measured by an investigator blinded to the treatment groups of the individual samples. RESULTS: In placebo-treated animals, the average luminal cross sectional area of the basilar artery was reduced by 68% after SAH as compared with controls (P < 0.0001). After SAH, the vasospastic response was attenuated in animals treated with 20 or 30 mg/kg representing a 28 or 35% reduction, respectively (P = 0.0011 and P = 0.0038). CONCLUSION: The results demonstrated that ABT-761 is effective in attenuating experimental cerebral vasospasm, indicating that this new drug represents a potential therapeutic agent for the treatment of vasospasm after SAH. | por |
| dc.identifier.citation | Neurosurgery. 2001 Nov;49(5):1205-12 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.4/943 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.subject | Hemorragia Subaracnóideia | por |
| dc.subject | Vasoespasmo Intracraniano | por |
| dc.title | The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- The_Novel_5_Lipoxygenase_Inhibitor_ABT_761.32.pdf
- Size:
- 200.9 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: